

Oregon Prescription Drug Monitoring Program 2020 3rd Quarter Report


Percentage change evaluated relative to 3rd Quarter, 2019

healthoregon.org/pdmp



Summary

- Registration has increased over the last year in all prescriber types (DDS/DMD, +5.8%; NP, +21.0%; MD/PA/DO, +9.3%; ND, +12.6%), pharmacists (+12.2%) and delegates (+38.3%) (Table 4).
- Web queries have decreased by 13.1% from the 3rd quarter of 2019; pharmacists (-28.3%), healthcare providers (-11.8%), and delegates (-4.4%) (Table 3).
- Integrated queries have increased dramatically across all clinical user groups except dentists; Pharmacists (+86.7%), ND (+278.1%), MD/PA/DO (+110.0%), NP/CNS-PP (+102.9%), DDS/DMD (+45.6%) (Table 4).
- Prescription trends for opioids were mixed (hydrocodone, -3.1%; oxycodone, +3.0%), while amphetamine increased (+9.6%); methylphenidate decreased (-1.2%) and benzodiazepine lorazepam increased (+3.4%), while others decreased or remained level; alprazolam (-2.5%) and clonazepam (+0.2%) (Table 5).
- Prescriptions have increased for buprenorphine (+33.8%) and naloxone (+24.7%), but have decreased for buprenorphine/naloxone combinations (-2.8%) (Table 6).



† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2020 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2019

healthoregon.org/pdmp



Table 1. PDMP Queries Summary Statistics: July-September, 2020

Measure	Web Portal	% Change*	Integrated	% Change*
Queries †	307,636	- 13.1 %	5,309,262	+ 66.9 %
Healthcare providers	81,520	- 11.8 %	4,469,505	+ 67.3 %
Pharmacies	71,539	- 28.3 %	839,757	+ 64.6 %
Delegates	154,513	- 4.4 %	-	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- Integrated Query data indicates that the number of integrated queries from healthcare providers and pharmacists has increased dramatically over the same quarter last year.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

Table 2. Special Requests: July-September, 2020

Measure	Count
Special Requests Total	76
Patient Records	10
Healthcare Board	66
Law Enforcement	4

- 80 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.
- The decrease in requests may be a consequence of COVID-19.

* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxR web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2020 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2019

healthoregon.org/pdmp



Table 3. PDMP Enrollment and System Use: July-September, 2020

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
All Prescribers	18,346	15,500 / 84.5 %	5,929 / 38.3 %	10,825 / 69.8 %	12,341 / 79.6 %
Top 4K Prescribers	4,000	3,867 / 96.7 %	2,431 / 62.9 %	3,337 / 86.3 %	3,624 / 93.7 %
Top 2K Prescribers	2,000	1,953 / 97.7 %	1,326 / 67.9 %	1,703 / 87.2 %	1,835 / 94 %

- During the 3rd quarter of 2020 there were 18,346 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 3rd quarter registration for the PDMP was high among all prescribers (84.5%), the top 4,000 prescribers (96.7%) and the top 2,000 prescribers (97.7%) reflecting the impact of mandatory registration.
- At the close of the 3rd quarter 79.6 % of enrolled prescribers queried the system; 93.7 % of the top 4,000 prescribers; 94 % of the top 2,000 prescribers through the web portal or integration.

Table 4. PDMP Query by Clinical User Group: July-September, 2020

Discipline	Total User Accounts	% Change*	Web Users ^{±†}	% Change*	Integrated Users	% Change*
MD/PA/DO	17,198	+ 9.3 %	1,902	- 26.6 %	12,094	+ 110.0 %
NP/CNS-PP	4,039	+ 21.0 %	946	- 8.2 %	2,758	+ 102.9 %
RPh	3,794	+ 12.2 %	1,560	- 18.2 %	239	+ 86.7 %
Delegates	3,414	+ 38.3 %	1,897	- 23.2 %	-	-
DDS/DMD	2,836	+ 5.8 %	435	- 8.4 %	233	+ 45.6 %
ND	590	+ 12.6 %	145	+ 2.8 %	397	+ 278.1 %

- PDMP registration has increased among all prescriber groups, pharmacists and delegates.
- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing across most groups.
- Integrated Users have increased over the past year across all clinical groups.

* Percentage change figures evaluated relative to the same time period during the prior year.

± Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2020 3rd Quarter Report

Percentage change evaluated relative to 3rd Quarter, 2019

healthoregon.org/pdmp



Table 5. Top Prescriptions: July-September, 2020

Drug	# of Rx	% of all Rx	% Change*
All	1,670,582	100.0 %	+ 17.1 %
Hydrocodone	253,387	15.2 %	-3.1 %
Oxycodone	231,316	13.8 %	+ 3.0 %
Gabapentin	218,065	13.1 %	-
Amphetamine	146,636	8.8 %	+ 9.6 %
Tramadol	85,682	5.1 %	- 1.2 %
Lorazepam	85,272	5.1 %	+ 3.4 %
Zolpidem	69,547	4.2 %	- 5.5 %
Methylphenidate	65,598	3.9 %	- 1.2 %
Alprazolam	63,617	3.8 %	- 2.5 %
Clonazepam	62,234	3.7 %	+ 0.2 %

- The number of prescriptions for oxycodone increased relative to the same quarter last year, while hydrocodone decreased.
- The number of prescriptions for benzodiazepine Lorazepam increased relative to the same quarter last year, while other benzodiazepines decreased or stayed the same.
- Prescriptions for amphetamine increased relative to the same quarter last year.
- Prescriptions for gabapentin reported increased reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

Table 6. Prescriptions for Buprenorphine and Naloxone: July-September, 2020

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	40,091	2.4 %	+ 33.8 %
Buprenorphine/Naloxone	23,960	1.4 %	- 2.8 %
Naloxone	4,193	0.3 %	+ 24.7 %

- Prescriptions for buprenorphine and naloxone have increased while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

* Percentage change figures evaluated relative to the same time period during the prior year